Dicynone tablets 250mg #100

Dicynone tablets instuction

Reed more and buy Dicynone tablets on this page

Composition

1 tablet contains: Active ingredient: etamzilat - 250.0 mg.
Excipients: citric acid anhydrous 12.5 mg; corn starch 65.0 mg; Povidone K25 10.0 mg; magnesium stearate 2.0 mg; lactose 60.5 mg.
Description
Round biconvex tablets of white or almost white color.
Pharmacotherapeutic group
Hemostatic agent.
ATX Code: B02BX01

Pharmacological properties

Pharmacodynamics

Etamzilat is a hemostatic, antihemorrhagic and angioprotective agent, normalizes the permeability of the vascular wall, improves microcirculation. Stimulates the formation of platelets and their release from the bone marrow. It increases the adhesion of platelets, stabilizes the walls of capillaries, thus reducing their permeability, inhibits the synthesis of prostaglandins that cause disaggregation of platelets, vasodilation and an increase in capillary permeability, which reduces bleeding time and reduces blood loss. Increases the rate of formation of the primary blood clot and enhances its retraction, practically does not affect the concentration of fibrinogen in the blood plasma and prothrombin time. With repeated use, thrombosis increases.
Etamzilat has virtually no effect on the composition of peripheral blood, its proteins and lipoproteins. The erythrocyte sedimentation rate may decrease slightly. Reduces the release of fluid and diapedes blood cells from the vascular bed, improves microcirculation. It has no vasoconstrictor action.
Possessing antihyaluronidase activity and stabilizing ascorbic acid, prevents the destruction and promotes the formation of mucopolysaccharides with a high molecular weight in the capillary wall, increases the resistance of capillaries, reduces their "fragility", normalizes permeability in pathological processes. This angioprotective effect is manifested in the treatment of various diseases associated with primary and secondary disorders of the microcirculation process.

Pharmacokinetics

After ingestion, Dicynone tablets are rapidly and almost completely absorbed.
The maximum plasma concentration after application of 500 mg is reached after 4 hours and is 15 μg / ml.
Almost completely penetrates the placental barrier. It is not known whether etamzilat penetrates into breast milk. About 95% of etamzilat binds to plasma proteins.
Etamzilat is slightly metabolized.
The half-life after oral administration is about 3.7 hours.
About 72% of the drug is excreted by the kidneys within 24 hours unchanged.
Clinical research on the use of etamzilat in patients with impaired liver and / or kidney function has not been conducted.

Indications for Dicynone tablets

Prevention and treatment of capillary bleeding of various etiologies:
• before and after surgical interventions on all well vascularized tissues in dental, otorhinolaryngological, gynecological, obstetric, urological, ophthalmological practice, plastic and reconstructive surgery;
• hematuria, metrorrhagia, primary menorrhagia, menorrhagia in women with intrauterine contraceptives (in the absence of organic pathology), nasal bleeding, gingival bleeding, vomiting of blood, melena.

Contraindications

• Hypersensitivity to Dicynone tablets.
• Acute porphyria.
• Hemoblastosis in children (lymphoblastic and myeloblastic leukemia, osteosarcoma).
• Thromboembolism, thrombosis.
• Rare hereditary forms of lactose intolerance, lactase deficiency or impaired glucose / galactose absorption (because the composition contains lactose).
• Children's age up to 3 years (for this dosage form).

Carefully

Thrombosis, thromboembolism in history; bleeding on the background of an overdose of anticoagulants, abnormal liver function and kidney (there is no clinical experience with the application).

Use during pregnancy and during breastfeeding

There are no clinical data on the possibility of using tablets Dicynone in pregnant women. Ditsinona use during pregnancy is possible only if the intended benefits to the mother outweigh the potential risk to the fetus.
There are no data regarding the allocation of etamzilat with breast milk.
Therefore, when using Dicynone tablets during lactation, it is necessary to resolve the issue of discontinuing breastfeeding.

Dosage and administration

Inside
The optimal daily dose of etamzilat for adults is 10-20 mg / kg body weight per day, divided into 3-4 doses. In most cases, a single dose of 250-500 mg (1-2 tablets), if necessary, a single dose can be increased to 750 mg (3 tablets).
Adults and teenagers (over 12 years old, weighing more than 40 kg)
In the preoperative period, 250-500 mg (1-2 tablets) for 1 hour before surgery.
In the postoperative period, 250-500 mg (1-2 tablets) every 4-6 hours until the risk of bleeding disappears.
To stop bleeding at 500 mg (2 tablets) every 8-12 hours (1000-1500 mg per day) with food or a small amount of water.
In the treatment of metro and menorrhagia 500 mg (2 tablets) 3 times a day (1500 mg per day) for 5-10 days.
Children from 3 to 12 years
Half the dose for adults.

Side effect

According to the World Health Organization (WHO), adverse effects are classified according to their development frequency as follows: often (> 1/100, <1/10), infrequently (> 1/1000, <1/100), rarely (> 1 / 10000, <1/1000) and very rarely (<1/10000), including individual messages.
From the digestive system
often: nausea, diarrhea, epigastric discomfort.
Skin and Subcutaneous Tissues
often: skin rash;
frequency unknown: facial flushing.
The nervous system
often: headache;
frequency is unknown: dizziness, paresthesia of the lower extremities.
Since the cardiovascular system
very rarely: thromboembolism;
frequency not known: marked reduction in blood pressure.
From the blood system and lymphatic system
very rarely: agranulocytosis, neutropenia, thrombocytopenia.
From the musculoskeletal system
rarely: arthralgia.
The immune system
very rare: allergic reactions.
Other
often: asthenia;
very rare: fever.
The side effects that occur during treatment are usually reversible with drug withdrawal.
In the case of the development of skin reactions or fever, it is necessary to discontinue therapy and inform the attending physician about it, since this may be a manifestation of a hypersensitivity reaction.

Overdose

To date, no cases of overdose have been described.
If an overdose occurs, it is necessary to begin symptomatic therapy.

Interaction with other drugs

There is still no data on the interaction of etamzilat with other drugs.
Perhaps a combination with aminocaproic acid and sodium menadione bisulfite.

special instructions for Dicynone tablets

Before starting treatment, other causes of bleeding should be excluded.
The drug is not effective in patients with thrombocytopenia.
For hemorrhagic complications associated with an overdose of anticoagulants, it is recommended to use specific antidotes.
Use of tabs Dicynone in patients with impaired blood coagulation is possible, but it must be supplemented by the introduction of drugs that eliminate the identified deficiency or defect of factors of blood coagulation.
Clinical studies on the use of pills Dicynone in patients with impaired liver and kidney function has not been conducted, so care should be taken when using etamsylate in this category of patients.
Special precautions for the destruction of unused drug is not required.

Influence on concentration

No special precautions required.

Release form

Tablets of 250 mg, on 10 tablets in the blister from aluminum / PVC / PVDH.
On 1, 2, 3, 5 or 10 blisters in a cardboard pack together with the application instruction.

Storage conditions

Store at a temperature not higher than 25 ° С, in a dry, dark place.
Keep out of the reach of children.
Shelf life - 5 years.
Do not apply after the expiration date.

Terms of sell

You can buy Dicynone tabs without a prescription.